# To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children

> **NCT01402713** · PHASE2,PHASE3 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 311 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **BIOLOGICAL:** GC1107
- **BIOLOGICAL:** TD_PUR INJ / SK Td vaccine

## Key facts

- **NCT ID:** NCT01402713
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 311 (ACTUAL)
- **Last updated:** 2015-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01402713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01402713, "To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01402713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*